JOP20210333A1 - جسم مضاد لـ EphA4 - Google Patents

جسم مضاد لـ EphA4

Info

Publication number
JOP20210333A1
JOP20210333A1 JOP/2021/0333A JOP20210333A JOP20210333A1 JO P20210333 A1 JOP20210333 A1 JO P20210333A1 JO P20210333 A JOP20210333 A JO P20210333A JO P20210333 A1 JOP20210333 A1 JO P20210333A1
Authority
JO
Jordan
Prior art keywords
epha4
antibody
epha4 antibody
mouse anti
cleavage
Prior art date
Application number
JOP/2021/0333A
Other languages
English (en)
Inventor
Toshio Imai
Eiji Inoue
Maki Deguchi
Tomomi Kawakatsu
Aki Nakatani
Akio Yamada
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of JOP20210333A1 publication Critical patent/JOP20210333A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير جسم مضاد لـ EphA4 يرتبط مع EphA4 ويُحسن انشقاق EphA4، بالإضافة إلى تركيبة صيدلانية تشتمل على الجسم المضاد كالمقوم النشط. يتم الحصول على جسم مضاد لـ EphA4 من فأر له ألفة ارتباط تجاه EphA4 ويمكنه تحسين انشقاق EphA4، ويتم تعيين المتوالية من منطقة التحديد التكميلية (CDR) للجسم المضاد لـ EphA4 من الفأر. بالتالي، يتم الحصول على الجسم المضاد لـ EphA4 المعني عن طريق إنتاج جسم مضاد مكتسب السمة البشرية من الجسم المضاد لـ EphA4 بالفأر. [الشكل الرئيسي] غير متوافر
JOP/2021/0333A 2019-07-01 2020-06-29 جسم مضاد لـ EphA4 JOP20210333A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019122982 2019-07-01
PCT/JP2020/025465 WO2021002312A1 (ja) 2019-07-01 2020-06-29 抗ＥｐｈＡ４抗体

Publications (1)

Publication Number Publication Date
JOP20210333A1 true JOP20210333A1 (ar) 2023-01-30

Family

ID=74066003

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0333A JOP20210333A1 (ar) 2019-07-01 2020-06-29 جسم مضاد لـ EphA4

Country Status (20)

Country Link
US (2) US10947313B2 (ar)
EP (1) EP3995582A4 (ar)
JP (2) JP6979147B2 (ar)
KR (1) KR20220027825A (ar)
CN (2) CN117398459A (ar)
AR (1) AR119303A1 (ar)
AU (1) AU2020300205A1 (ar)
BR (1) BR112021025161A2 (ar)
CA (1) CA3139398A1 (ar)
CL (1) CL2021003326A1 (ar)
CO (1) CO2021016588A2 (ar)
IL (1) IL287828A (ar)
JO (1) JOP20210333A1 (ar)
MA (1) MA56466A (ar)
MX (1) MX2021015298A (ar)
PE (1) PE20220570A1 (ar)
SG (1) SG11202112433VA (ar)
TW (3) TW202342101A (ar)
WO (1) WO2021002312A1 (ar)
ZA (1) ZA202108836B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112433VA (en) 2019-07-01 2021-12-30 Eisai R&D Man Co Ltd ANTI-EphA4 ANTIBODY
TW202241503A (zh) * 2020-12-24 2022-11-01 日商衛材R&D企管股份有限公司 肌肉萎縮性側索硬化症之治療用醫藥組合物
AU2022388189A1 (en) * 2021-11-11 2024-05-02 Eisai R&D Management Co., Ltd. Anti-epha4 antibody

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1094731A (en) 1911-06-06 1914-04-28 Lucien Linden Oxidizing process.
JP2824433B2 (ja) 1988-12-09 1998-11-11 財団法人化学及血清療法研究所 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター
CA1339413C (en) 1988-06-24 1997-09-02 Junichi Miyazaki Exogenous gene expression vector containing chick .beta.-actin gene promoter
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5902732A (en) 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US20020068361A1 (en) 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
US20070026409A1 (en) 2001-08-14 2007-02-01 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
JP2003169699A (ja) 2001-12-10 2003-06-17 Japan Science & Technology Corp 特異的γプロテアーゼ阻害剤のスクリーニング方法
JP2004000060A (ja) 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
JP2006507256A (ja) 2002-09-24 2006-03-02 ザ バーナム インスティチュート Ｅｐｈ受容体活性を調節する新規薬剤
AU2003283619A1 (en) 2002-11-26 2004-06-18 Pharmacia & Upjohn Company Soluble notch-based substrates for gamma secretase and methods and compositions for using same
AU2004291026A1 (en) 2003-06-06 2005-06-02 Medimmune, Llc Use of EphA4 and modulator of EphA4 for diagnosis, treatment and prevention of cancer
WO2005045028A1 (ja) 2003-11-10 2005-05-19 Osaka Industrial Promotion Organization セル・フリー・Ｎｏｔｃｈ切断分析方法及び薬剤スクリーニング方法
US20070253954A1 (en) 2004-02-27 2007-11-01 Oncotherapy Science, Inc. Epha4 As Therapeutic Target Of Prc And Pdaca
WO2006026820A1 (en) 2004-09-08 2006-03-16 The University Of Queensland Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
GB0427023D0 (en) 2004-12-09 2005-01-12 Merck Sharp & Dohme Assay method
BRPI0708311A2 (pt) 2006-02-28 2011-05-24 Oncotherapy Science Inc métodos para danificar células usando funções efetoras de anticorpos anti-epha4
EP1947193A1 (en) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
ATE546543T1 (de) 2007-06-08 2012-03-15 Eisai R&D Man Co Ltd Screening-verfahren mit verwendung des neuen substrats epha4 für gamma-sekretase
CA2692604A1 (en) 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
US20090191580A1 (en) 2007-07-19 2009-07-30 Eisai R & D Management Co., Ltd. METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE
EP2192181A4 (en) 2007-08-01 2010-12-08 Eisai R&D Man Co Ltd SCREENING METHOD USING THE NEW C-RET SUBSTRATE FOR GAMMA-SECRETASE
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US20090163594A1 (en) 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
WO2009064006A1 (ja) 2007-11-15 2009-05-22 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質EphA7を利用したスクリーニング方法
DK2223999T3 (en) 2007-11-30 2017-12-18 Eisai R&D Man Co Ltd EPHA4 POLYPEPTIDE WITH UNKNOWN ACTIVITY AND USE THEREOF
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2260864A1 (en) 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
JP2010285413A (ja) 2009-06-10 2010-12-24 Univ Of Melbourne 治療用途
JP6059017B2 (ja) * 2010-12-17 2017-01-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法
JP5961608B2 (ja) 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
GB201107996D0 (en) 2011-05-13 2011-06-29 Vib Vzw EphA4 is a diease modifier in motor neuron disease
ES2925224T3 (es) * 2014-07-31 2022-10-14 Us Gov Health & Human Services Anticuerpos monoclonales humanos contra EphA4 y su uso
US10428140B2 (en) * 2015-09-08 2019-10-01 Eisai R&D Management Co., Ltd. Anti-EphA4 antibody
SG11202112433VA (en) 2019-07-01 2021-12-30 Eisai R&D Man Co Ltd ANTI-EphA4 ANTIBODY

Also Published As

Publication number Publication date
CO2021016588A2 (es) 2022-04-08
CN117398459A (zh) 2024-01-16
JP2022031271A (ja) 2022-02-18
PE20220570A1 (es) 2022-04-20
CA3139398A1 (en) 2021-01-07
SG11202112433VA (en) 2021-12-30
TW202248216A (zh) 2022-12-16
AR119303A1 (es) 2021-12-09
TW202342101A (zh) 2023-11-01
TW202115116A (zh) 2021-04-16
AU2020300205A1 (en) 2022-01-20
IL287828A (en) 2022-01-01
BR112021025161A2 (pt) 2022-01-25
TWI808882B (zh) 2023-07-11
CN113906050A (zh) 2022-01-07
JP7072114B2 (ja) 2022-05-19
CN113906050B (zh) 2023-11-21
JP6979147B2 (ja) 2021-12-08
ZA202108836B (en) 2023-04-26
MA56466A (fr) 2022-05-11
KR20220027825A (ko) 2022-03-08
TWI779307B (zh) 2022-10-01
JPWO2021002312A1 (ja) 2021-09-13
US10947313B2 (en) 2021-03-16
CL2021003326A1 (es) 2022-07-22
US20210002378A1 (en) 2021-01-07
MX2021015298A (es) 2022-01-18
EP3995582A4 (en) 2023-01-18
EP3995582A1 (en) 2022-05-11
US20210171644A1 (en) 2021-06-10
US11136400B2 (en) 2021-10-05
WO2021002312A1 (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
JOP20210333A1 (ar) جسم مضاد لـ EphA4
CR20210326A (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
PH12020500177A1 (en) Bcma monoclonal antibody-drug conjugate
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
CR20210199A (es) Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente
MX2017012615A (es) Anticuerpo anti-notch4 humano.
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
AU2016319433A8 (en) Anti-EphA4 antibody
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
WO2010124163A3 (en) Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
WO2019005817A3 (en) HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
WO2022031940A3 (en) Il28ra binding molecules and methods of use
WO2019171253A8 (en) Anti-pd-1 antibody compositions
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
MX2023004054A (es) Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
CR20220421A (es) Anticuerpos anti-cd19 humano
EP3825333A4 (en) LOW FUNCTIONALITY ADCC/CDC MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE
MX2021012365A (es) Anticuerpos biespecificos.
MX2021014433A (es) Molecula de union a sitio de escision de anticuerpo.